{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.7","upperLimit":"76.7","value":"60.0"},{"groupId":"OG001","lowerLimit":"30.0","upperLimit":"60.0","value":"44.4"},{"groupId":"OG002","lowerLimit":"23.7","upperLimit":"51.4","value":"34.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"223"},{"groupId":"OG002","value":"222"}],"units":"Participants"}],"description":"Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes into daily electronic diaries. If MJS duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit is calculated. A decrease in duration of MJS indicated an improvement in the participant's condition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEDIAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug and had at least 4 entries within any post-baseline 7-day window are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Mean Duration of Morning Joint Stiffness(MJS) in the Prior 7 Days as Collected in Electronic Daily Diaries","type":"SECONDARY","unitOfMeasure":"minutes"}